Debates continue over Gilead and Arcus' TIGIT combo despite updated data at ASCO23.
TL;DR
Gilead and Arcus presented updated data on their experimental cancer immunotherapy combo, which showed lower progression-free survival rates than the previous update. The anti-TIGIT/anti-PD-L1 combo, positioned as a first-line treatment for non-small cell lung cancer, recorded data that drew mixed reactions. The latest analysis, presented at ASCO, included only a handful more patients than the previous update, but PFS rates fell.
- Gilead, Arcus’ updated TIGIT data unlikely to resolve debates around space: #ASCO23 Endpoints News
- Asco 2023 – Roche sees Morpheus and takes the red pill Evaluate Pharma
- ASCO: Gilead and Arcus's Cancer Immunotherapy Combo Faces Scrutiny Over Lower Survival Rates BioSpace
- Gilead and Arcus' TIGIT combo continues to show signs of life FierceBiotech
- Gilead and Arcus Announce Anti-TIGIT Domvanalimab Continues to Demonstrate Consistent Improvement in Progression-Free Survival in Non-Small Cell Lung Cancer Study Business Wire
- View Full Coverage on Google News
Want the full story? Read the original reporting
Read on Endpoints News